JULIE STODDARD: Open Payments
NPI 1689362998 · SALAMANCA, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$837 in 42 payments from 11 companies in 2025. Trend: 2023 $562 · 2024 $4,061 · 2025 $837
Food & beverage: $837
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 12 | $319 |
| Sumitomo Pharma America, Inc. | 13 | $144 |
| ABBVIE INC. | 3 | $61 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $59 |
| Kowa Pharmaceuticals America, Inc. | 2 | $57 |
| Novo Nordisk Inc | 2 | $53 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $42 |
| Lilly USA, LLC | 2 | $36 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $24 |
| Amgen Inc. | 1 | $23 |
Products named: GEMTESA, FARXIGA, BREZTRI, TEZSPIRE, AIRSUPRA, Kerendia, ZORYVE, Ozempic.
Industry payments across NY — which companies pay providers there.
